President Donald Trump recently signed an executive order aimed at encouraging expanded research into psychedelic drugs, part of a broader push to explore emerging mental health treatment. The president also announced that the federal government is making a $50 million investment for further research into the psychedelic drug ibogaine. Long whispered about in alternative healing circles and quietly sought out by veterans and addiction patients abroad, the psychoactive compound is now being fast-tracked into the American medical conversation.
The order directs federal agencies to accelerate research and streamline regulatory…
